Given the cancer immunoprevention potential of the MUC1 peptide vaccine response, characterized by a reduction of adenoma recurrence (15), the differentially expressed genes and regulated pathways we identified hold promise as therapeutic targets for vaccine non-responders. The gene discussed is MUC1; the disease is adenoma.